Compare
Apimeds Pharmaceuticals US, Inc. vs Cypherpunk Technologies Inc. vs Transcode Therapeutics, Inc. vs Gyre Therapeutics, Inc.
| Latest fiscal year | Apimeds Pharmaceuticals US, Inc. APUS | Cypherpunk Technologies Inc. CYPH | Transcode Therapeutics, Inc. RNAZ | Gyre Therapeutics, Inc. GYRE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $116.59M |
| Revenue growth (YoY) | n/a | n/a | n/a | +10.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | 9.9% |
| Net margin | n/a | n/a | n/a | 8.5% |
| Net income | -$6.00M | $4.82M | -$34.66M | $9.88M |
| EPS (Diluted) | -$0.55 | $0.07 | -$52.59 | $0.02 |
| Operating cash flow | -$8.93M | -$43.90M | -$19.52M | $1.01M |
| Free cash flow | -$8.98M | n/a | -$19.52M | -$180.0K |
| Cash & equivalents | $1.64M | $14.04M | $17.81M | $37.07M |
| Total assets | $164.18M | $163.18M | $162.40M | $166.13M |
| Total liabilities | $10.84M | $9.68M | $10.52M | $23.85M |
| Shareholders' equity | $153.35M | $153.51M | $10.34M | $106.03M |
| Return on year-end equity | -3.9% | 3.1% | -335.4% | 9.3% |
| Shares outstanding | 12.58M | 83.85M | 917.0K | 91.31M |
Revenue, most recent five fiscal years
| Fiscal year | Apimeds Pharmaceuticals US, Inc. | Cypherpunk Technologies Inc. | Transcode Therapeutics, Inc. | Gyre Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $1.50M Ended 2021-12-31 | n/a | $116.59M Ended 2025-12-31 |
| 1 year earlier | n/a | $1.50M Ended 2020-12-31 | n/a | $105.76M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $113.45M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $102.29M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $7.34M Ended 2021-12-31 |